GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Cyclically Adjusted Revenue per Share

Trinity Biotech (Trinity Biotech) Cyclically Adjusted Revenue per Share : $20.95 (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Trinity Biotech's adjusted revenue per share for the three months ended in Sep. 2023 was $1.915. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $20.95 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Trinity Biotech's average Cyclically Adjusted Revenue Growth Rate was 0.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Trinity Biotech was 11.80% per year. The lowest was -21.20% per year. And the median was -6.80% per year.

As of today (2024-04-27), Trinity Biotech's current stock price is $1.83. Trinity Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $20.95. Trinity Biotech's Cyclically Adjusted PS Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Trinity Biotech was 3.44. The lowest was 0.09. And the median was 1.06.


Trinity Biotech Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Trinity Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Cyclically Adjusted Revenue per Share Chart

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.50 19.35 19.08 20.43 21.13

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.93 21.13 21.21 21.19 20.95

Competitive Comparison of Trinity Biotech's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Trinity Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cyclically Adjusted PS Ratio falls into.



Trinity Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Trinity Biotech's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=1.915/120.7077*120.7077
=1.915

Current CPI (Sep. 2023) = 120.7077.

Trinity Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 5.155 99.875 6.230
201403 5.168 100.573 6.203
201406 5.490 100.773 6.576
201409 5.736 100.474 6.891
201412 5.627 99.576 6.821
201503 5.346 99.975 6.455
201506 4.210 100.573 5.053
201509 4.478 100.274 5.391
201512 4.346 99.676 5.263
201603 4.103 99.676 4.969
201606 4.627 101.072 5.526
201609 4.603 100.274 5.541
201612 4.224 99.676 5.115
201703 4.301 100.374 5.172
201706 4.694 100.673 5.628
201709 4.806 100.474 5.774
201712 4.647 100.075 5.605
201803 4.548 100.573 5.459
201806 4.779 101.072 5.707
201809 4.532 101.371 5.397
201812 4.898 100.773 5.867
201903 4.324 101.670 5.134
201906 4.416 102.168 5.217
201909 4.828 102.268 5.699
201912 4.185 102.068 4.949
202003 4.157 102.367 4.902
202006 3.090 101.769 3.665
202009 6.082 101.072 7.264
202012 7.839 101.072 9.362
202103 5.649 102.367 6.661
202106 6.183 103.364 7.220
202109 5.040 104.859 5.802
202112 4.671 106.653 5.287
202203 3.189 109.245 3.524
202206 2.270 112.734 2.431
202209 2.060 113.431 2.192
202212 3.667 115.425 3.835
202303 1.943 117.618 1.994
202306 1.815 119.611 1.832
202309 1.915 120.708 1.915

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Trinity Biotech  (NAS:TRIB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Trinity Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.83/20.95
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Trinity Biotech was 3.44. The lowest was 0.09. And the median was 1.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Trinity Biotech Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.